XWELL, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that XWELL, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.21M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $33.90M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $30.11M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $55.94M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $73.73M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.39M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $48.52M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $50.09M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $48.82M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $11.99M | Mar 29, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.21M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $33.90M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $30.11M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $7.47M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $55.94M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $73.73M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.39M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $48.52M | Mar 31, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $7.75M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $937.0K | Mar 30, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.51M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $8.92M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $3.68M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $1.09M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $12.05M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $32.34M | Apr 17, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.99M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($16.85M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($27.74M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($11.53M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($32.84M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.35M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($90.49M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($21.22M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($37.21M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($28.84M) | Apr 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.67M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($16.71M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($28.21M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($12.09M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($31.16M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $4.11M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($40.10M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.87M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($34.73M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($14.72M) | Apr 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $889.0K | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $1.51M | Mar 16, 2015 |
| FY2014 | Dec 31, 2012 | $543.0K | Mar 16, 2015 |
| FY2012 | Dec 31, 2011 | $0 | Mar 21, 2013 |
| FY2011 | Dec 31, 2010 | $2.50M | Mar 30, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.00M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $20.08M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $12.96M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $21.18M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $24.20M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $15.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.32M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $16.24M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $16.58M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.70M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.71M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($11.01M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($16.07M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($12.87M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($24.19M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $14.56M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($25.01M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($113.0K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($6.57M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($12.17M) | Apr 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.96M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $1.78M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $1.91M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $1.64M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $6.46M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $4.28M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.28M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.03M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $4.48M | Apr 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.22M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $25.35M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $38.99M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $42.94M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $70.43M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $127.27M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $103.13M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $28.72M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $30.58M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $65.24M | Apr 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.80M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $17.61M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $18.02M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $17.28M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $22.48M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $27.33M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $22.76M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $31.26M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $17.45M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $19.40M | Apr 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.26M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($788.0K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $13.00M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $17.79M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $39.93M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $92.73M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $77.81M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.24M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.11M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $40.88M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $1.39M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $1.37M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $4.02M | Apr 16, 2024 |
| FY2018 | Dec 31, 2018 | $0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $19.63M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $20.30M | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2014 | $0 | Mar 30, 2017 |
| FY2015 | Dec 31, 2013 | $67.76M | Mar 10, 2016 |
| FY2013 | Dec 31, 2012 | $65.97M | Mar 10, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($489.70M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($472.71M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($455.85M) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | ($450.88M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($428.11M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($395.28M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($398.62M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($308.14M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($286.91M) | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | ($249.71M) | Apr 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.62M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $4.55M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $8.44M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | $4.83M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $19.04M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $105.51M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $89.80M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.18M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.40M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | $6.37M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $3.58M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $5.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.76M | Mar 31, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | (2) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | (7) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 31, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | (1) | Mar 30, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | (2) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | (7) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 31, 2022 |
| FY2016 | Dec 31, 2016 | (1) | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | (1) | Mar 30, 2017 |
| FY2014 | Dec 31, 2014 | 0 | Mar 16, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.07M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 5.26M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 4.18M | Apr 15, 2025 |
| FY2023 | Sep 30, 2023 | 4.17M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 4.16M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 101.27M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 94.06M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 5.16M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 1.76M | Apr 20, 2020 |
| FY2018 | Dec 31, 2017 | 1.33M | Apr 1, 2019 |